Neuron Activation Agent for Neural Cell Transplantation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for neural cell transplantation, such as those for treating neurodegenerative diseases, face challenges with low survival rates and low differentiation of transplanted cells into mature neurons, limiting therapeutic effectiveness.
Innovation Solution
An agent comprising specific proteins like Lysozyme (LYZ), Secreted phosphoprotein 1 (SPP1), Progranulin (PGrn), Cathepsin D (Ctsd), Cathepsin S (Ctss), Apolipoprotein D (Apod), and Sparc, or their active fragments, is used to promote neuron activation, survival, differentiation, and maturation, enhancing the success of cell transplantation by increasing the density and functionality of transplanted dopaminergic neurons.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cell transplantation is performed to supplement neurons, then the potential for restoring brain functions is improved, but the survival rate of transplanted cells and differentiation into mature neurons remains low
Solution Approach 1:
The patent introduces a specific protein (LYZ2 or its active fragment) as an intermediary substance that mediates between the transplanted neural stem cells and the host brain environment. This intermediary protein creates favorable conditions for cell survival and differentiation, resolving the contradiction by facilitating the transition from low survival/differentiation to high survival/differentiation states.
Solution Approach 2:
The patent changes the biochemical parameters of the transplantation environment by introducing the LYZ2 protein, which modifies the local microenvironment to support neuronal survival and differentiation. This parameter change transforms the hostile or suboptimal transplantation environment into a supportive one, simultaneously improving both survival rate and differentiation efficiency.
2Ease of manufacture
If conventional transplantation methods are used, then the procedure can be performed, but the therapeutic effect is limited due to low cell survival and maturation
Solution Approach 1:
The patent applies preliminary action by administering the LYZ2 protein before or during the transplantation procedure. This preparatory measure ensures that the transplantation environment is optimized in advance, allowing cells to survive and differentiate more effectively once implanted, thereby enhancing therapeutic effect without complicating the procedure.
Solution Approach 2:
The LYZ2 protein serves as a mediator that bridges the gap between the simple transplantation procedure and the desired therapeutic outcome. It facilitates cell survival and maturation in the host brain environment, enabling conventional transplantation methods to achieve improved therapeutic effects.
Data Source
AI summary
Developing an agent for activating a neuron which activates a brain neuron. The agent is suitable for promoting cell transplantation for a neural disease, survival of a transplanted cell, differentiation of the transplanted cell into a neuronal cell, and/or maturation of the neuron. The agent for activating the neuron contains a protein selected from the group consisting of Lysozyme (LYZ), Secreted phosphoprotein 1 (SPP1), Progranulin (PGrn), Cathepsin D (Ctsd), Cathepsin S (Ctss), Apolipoprotein D (Apod), Sparc, CD52, Macrophage expressed gene 1 (MPEG1), C-C motif chemokine ligand 2 (CCL2), Cystatin F (CST7), Ras family small GTPase 2 (RAC2), Serpin family A member 3 (SERPINA3), Anosmin 1 (ANOS1), Kallikrein-related peptidase 6 (KLK6), Alpha-2-macroglobulin (A2M), GM14295, Galectin 3-binding protein (LGALS3BP), Apolipoprotein C1 (APOC1), and orthologs thereof, or an active fragment thereof, or a nucleic acid encoding the protein or active fragment thereof, and an agent for assisting cell transplantation containing the agent.